AR045957A1 - Composicion farmaceutica y combinacion - Google Patents
Composicion farmaceutica y combinacionInfo
- Publication number
- AR045957A1 AR045957A1 ARP040103556A ARP040103556A AR045957A1 AR 045957 A1 AR045957 A1 AR 045957A1 AR P040103556 A ARP040103556 A AR P040103556A AR P040103556 A ARP040103556 A AR P040103556A AR 045957 A1 AR045957 A1 AR 045957A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- prodrug
- salt
- mycophenolic acid
- combination
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 6
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 abstract 4
- 229960000951 mycophenolic acid Drugs 0.000 abstract 4
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical group OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002702 enteric coating Substances 0.000 abstract 1
- 238000009505 enteric coating Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000009261 transgenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0323202A GB0323202D0 (en) | 2003-10-03 | 2003-10-03 | Organic compounds |
| GB0323598A GB0323598D0 (en) | 2003-10-08 | 2003-10-08 | Organic compounds |
| GB0329852A GB0329852D0 (en) | 2003-12-23 | 2003-12-23 | Organic compounds |
| GB0405902A GB0405902D0 (en) | 2004-03-16 | 2004-03-16 | Organic compounds |
| GB0410714A GB0410714D0 (en) | 2004-05-13 | 2004-05-13 | Organic compounds |
| GB0419356A GB0419356D0 (en) | 2004-08-31 | 2004-08-31 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045957A1 true AR045957A1 (es) | 2005-11-16 |
Family
ID=34437795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103556A AR045957A1 (es) | 2003-10-03 | 2004-09-30 | Composicion farmaceutica y combinacion |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070036857A1 (enExample) |
| EP (1) | EP1670437A1 (enExample) |
| JP (1) | JP2007507458A (enExample) |
| AR (1) | AR045957A1 (enExample) |
| AU (1) | AU2004280078B2 (enExample) |
| BR (1) | BRPI0414864A (enExample) |
| CA (1) | CA2538099A1 (enExample) |
| MX (1) | MXPA06003646A (enExample) |
| PE (1) | PE20050755A1 (enExample) |
| TW (1) | TW200520759A (enExample) |
| WO (1) | WO2005034916A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2006086498A2 (en) * | 2005-02-08 | 2006-08-17 | Aspreva Pharmaceuticals Sa | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| KR20080094788A (ko) * | 2006-02-13 | 2008-10-24 | 노파르티스 아게 | 고복용량의 미코페놀산(엠피에이) |
| CA2669415A1 (en) * | 2006-11-14 | 2008-05-22 | Ariad Pharmaceuticals, Inc. | Solid dosage form comprising ap23573 |
| AU2008288106B2 (en) * | 2007-08-13 | 2012-03-15 | Panacea Biotec Limited | Extended release compositions comprising mycophenolate sodium and processes thereof |
| CN101969931A (zh) * | 2008-03-05 | 2011-02-09 | 万能药生物有限公司 | 包含霉酚酸的调节释放药物组合物及其方法 |
| EP2446027A1 (en) * | 2009-06-25 | 2012-05-02 | Danisco A/S | Protein |
| EA201270544A1 (ru) * | 2009-10-13 | 2012-09-28 | Тева Фармасьютикал Индастриз Лтд. | Композиции с отсроченным высвобождением |
| US10391059B2 (en) | 2009-11-11 | 2019-08-27 | Rapamycin Holdings, Inc. | Oral rapamycin nanoparticle preparations and use |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| EP2763663B1 (en) * | 2011-10-06 | 2017-12-27 | Novartis AG | Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin |
| JP2015533174A (ja) * | 2012-10-11 | 2015-11-19 | セラヴィダ，インコーポレイテッド | ピロカルピンの医薬製剤 |
| TW201503912A (zh) | 2013-03-19 | 2015-02-01 | Novartis Ag | 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物 |
| WO2014167442A1 (en) * | 2013-03-26 | 2014-10-16 | Wockhardt Limited | Pharmaceutical compositions comprising mycophenolic acid or salts thereof |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| US10576076B2 (en) | 2015-05-20 | 2020-03-03 | Novartis Ag | Pharmaceutical combination of everolimus with dactolisib |
| JP2020500930A (ja) | 2016-11-23 | 2020-01-16 | ノバルティス アーゲー | エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法 |
| MX2019010829A (es) * | 2017-03-13 | 2020-02-05 | Okava Pharmaceuticals Inc | Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos. |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| US11446055B1 (en) | 2018-10-18 | 2022-09-20 | Lumoptik, Inc. | Light assisted needle placement system and method |
| US20250282721A9 (en) * | 2021-12-23 | 2025-09-11 | Gencaps Sàrl | Drug delivery system comprising monomethyl fumarate |
| WO2023224914A1 (en) * | 2022-05-16 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Assessing and treating caveolinopathy diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2086642C (en) * | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5283257A (en) * | 1992-07-10 | 1994-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating hyperproliferative vascular disease |
| PL177323B1 (pl) * | 1993-10-01 | 1999-10-29 | Syntex Inc | Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| CN1233169A (zh) * | 1996-10-14 | 1999-10-27 | 弗·哈夫曼-拉罗切有限公司 | 一种粉末状制剂的制备工艺 |
| US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000067773A2 (en) * | 1999-05-10 | 2000-11-16 | Novartis Ag | Combinations of immunosupressive agents for the treatment or prevention of graft rejections |
| US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
| US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| JP2005514411A (ja) * | 2002-01-10 | 2005-05-19 | ノバルティス アクチエンゲゼルシャフト | ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム |
| SI1539157T1 (sl) * | 2002-09-18 | 2013-11-29 | Trustees Of The University Of Pennsylvania | Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije |
| CA2500908A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
| GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
| GB0307553D0 (en) * | 2003-04-01 | 2003-05-07 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-30 AR ARP040103556A patent/AR045957A1/es unknown
- 2004-10-01 AU AU2004280078A patent/AU2004280078B2/en not_active Ceased
- 2004-10-01 BR BRPI0414864-9A patent/BRPI0414864A/pt not_active IP Right Cessation
- 2004-10-01 PE PE2004000963A patent/PE20050755A1/es not_active Application Discontinuation
- 2004-10-01 JP JP2006530072A patent/JP2007507458A/ja active Pending
- 2004-10-01 US US10/570,752 patent/US20070036857A1/en not_active Abandoned
- 2004-10-01 TW TW093129854A patent/TW200520759A/zh unknown
- 2004-10-01 WO PCT/EP2004/010998 patent/WO2005034916A1/en not_active Ceased
- 2004-10-01 EP EP04765757A patent/EP1670437A1/en not_active Withdrawn
- 2004-10-01 MX MXPA06003646A patent/MXPA06003646A/es not_active Application Discontinuation
- 2004-10-01 CA CA002538099A patent/CA2538099A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1670437A1 (en) | 2006-06-21 |
| BRPI0414864A (pt) | 2006-11-28 |
| JP2007507458A (ja) | 2007-03-29 |
| MXPA06003646A (es) | 2006-06-05 |
| AU2004280078A1 (en) | 2005-04-21 |
| WO2005034916A1 (en) | 2005-04-21 |
| TW200520759A (en) | 2005-07-01 |
| US20070036857A1 (en) | 2007-02-15 |
| CA2538099A1 (en) | 2005-04-21 |
| PE20050755A1 (es) | 2005-11-28 |
| AU2004280078B2 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395136B (es) | Composiciones farmaceuticas y metodos de administracion relacionados. | |
| AR080721A1 (es) | 1-((3-ciano-piridin-2-il) metil]-3-metil-7-(2-butin-1-il)-8- (3-(r)- amino-piperidin-1-il)- xantina para tratamiento de un trastorno metabolico de un animal no humano predominantemente carnivoro | |
| NZ606825A (en) | Methods and compositions for treating complement-associated disorders | |
| PE20180130A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| WO2011118976A3 (en) | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same | |
| ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| WO2006037031A3 (en) | Formulations and methods for treatment of inflammatory diseases | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
| MX2007016462A (es) | Composiciones topicas para tratar la piel. | |
| ATE554778T1 (de) | Verfahren, pharmazeutische zusammensetzungen und hergestellte artikel zur verabreichung von therapeutischen zellen an das zentrale nervensystem eines tiers | |
| WO2010082787A2 (ko) | 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물 | |
| RU2020121715A (ru) | Синтез эластического волокна in vivo | |
| MX2021016055A (es) | Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis. | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| MX2010001711A (es) | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| PE20060507A1 (es) | Composicion farmaceutica que contiene acido micofenolico con recubrimiento de liberacion modificada | |
| WO2013085849A3 (en) | Sulfate esters of noribogaine | |
| WO2014165723A3 (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| EP1829882A3 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
| MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
| TR200900878A2 (tr) | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar | |
| AR044209A1 (es) | Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |